# A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

> **NCT04961996** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 4170 (actual)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** Giredestrant
- **DRUG:** Physician's Choice of Endocrine Therapy
- **DRUG:** LHRH Agonist

## Key facts

- **NCT ID:** NCT04961996
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-27
- **Primary completion:** 2025-08-08
- **Final completion:** 2035-01-01
- **Target enrollment:** 4170 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04961996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04961996, "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04961996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*